Literature DB >> 4593769

The effect of spironolactone on antipyrine metabolism in man.

D H Huffman, D W Shoeman, P Pentikäinen, D L Azarnoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4593769     DOI: 10.1159/000136455

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


× No keyword cloud information.
  26 in total

1.  Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.

Authors:  G W Hepner; E S Vesell
Journal:  Am J Dig Dis       Date:  1975-01

2.  Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats.

Authors:  H F VOHRINGER; L Weller; N Rietbrock
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1975       Impact factor: 3.000

3.  Pharmacokinetics of drugs in patients with the nephrotic syndrome.

Authors:  R Gugler; D W Shoeman; D H Huffman; J B Cohlmia; D L Azarnoff
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

4.  Pharmacokinetics of diazepam in disordered liver function.

Authors:  P B Andreasen; J Hendel; G Greisen; E F Hvidberg
Journal:  Eur J Clin Pharmacol       Date:  1976-06-15       Impact factor: 2.953

5.  Measurement of urinary 6-beta-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin.

Authors:  E E Ohnhaus; B K Park
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

Review 6.  Influence of sex on drug kinetics in man.

Authors:  J F Giudicelli; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1977 May-Jun       Impact factor: 6.447

7.  Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative.

Authors:  D Vital Durand; C Hampden; A R Boobis; B K Park; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

8.  The effect of spironolactone on the liver microsomal enzyme system in patients.

Authors:  E E Ohnhaus; E Gerber-Taras
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

Review 9.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 10.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.